Section Arrow
UPB.NASDAQ
- Upstream Bio Inc
Quotes are at least 15-min delayed:2026/01/05 08:53 EST
Pre Market
Last
 26.8
-0.27 (-1.00%)
Bid
26.85
Ask
30.41
High 26.8 
Low 26.8 
Volume 124 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
27.07 
1-M High
-- 
Volume 
-- 
Bid
26.85
Ask
30.41
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
1.46B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.40/-2.48
Enterprise Value
1.46B
Balance Sheet
Book Value Per Share
7.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.21M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 26.8 +0.18 +0.68%
ZVRAZevra Therapeutics-------- 
Pre Market 8.475 +0.135 +1.62%
ZURAZura Bio Limited-------- 
Pre Market 5.69 +0.14 +2.52%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 1.4 +0.03 +2.19%
ZLABZai Lab Limited-------- 
Pre Market 18.01 +0.68 +3.92%
Industry overview quotes are at least 15 minutes delayed
Business Description
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.